التفاصيل البيبلوغرافية
| العنوان: |
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. |
| المؤلفون: |
Gowen, Michael F., Giles, Keith M., Simpson, Danny, Tchack, Jeremy, Zhou, Hua, Moran, Una, Dawood, Zarmeena, Pavlick, Anna C., Hu, Shaohui, Wilson, Melissa A., Zhong, Hua, Krogsgaard, Michelle, Kirchhoff, Tomas, Osman, Iman |
| المصدر: |
Journal of Translational Medicine; 4/2/2018, Vol. 16 Issue 1, p1-1, 1p |
| مصطلحات موضوعية: |
MELANOMA, IMMUNOGLOBULINS, SUPPORT vector machines, PHENOTYPES, MICRORNA, PATIENTS |
| مستخلص: |
Background: Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience immune-related adverse events (irAEs), which can be severe and result in treatment termination. To date, no biomarker exists that can predict development of irAEs.Methods: We hypothesized that pre-treatment antibody profiles identify a subset of patients who possess a sub-clinical autoimmune phenotype that predisposes them to develop severe irAEs following immune system disinhibition. Using a HuProt human proteome array, we profiled baseline antibody levels in sera from melanoma patients treated with anti-CTLA-4, anti-PD-1, or the combination, and used support vector machine models to identify pre-treatment antibody signatures that predict irAE development.Results: We identified distinct pre-treatment serum antibody profiles associated with severe irAEs for each therapy group. Support vector machine classifier models identified antibody signatures that could effectively discriminate between toxicity groups with > 90% accuracy, sensitivity, and specificity. Pathway analyses revealed significant enrichment of antibody targets associated with immunity/autoimmunity, including TNFα signaling, toll-like receptor signaling and microRNA biogenesis.Conclusions: Our results provide the first evidence supporting a predisposition to develop severe irAEs upon immune system disinhibition, which requires further independent validation in a clinical trial setting. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Translational Medicine is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder